The Form 144 filing by a founding venture investor, combined with heavy insider selling over the past month, suggests potential continued distribution. Monitor for subsequent Form 4 filings to confirm actual sales, and watch for any operational updates or clinical data that could offset the negative signal.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 29 $17.41entry
- T+1 · 7mo ago +0.80%α −0.22% · $17.55
- T+5 · 7mo ago +8.21%α +5.10% · $18.84
- T+20 · 6mo ago +6.61%α +0.56% · $18.56
- T+60 · 4mo ago +40.38%α +36.27% · $24.44
Price Chart
How similar events traded
Executive Summary
Atlas Venture Opportunity Fund I, L.P., a major venture capital backer of Dyne Therapeutics, filed a Form 144 notice of intent to sell 47,103 shares of common stock, with an approximate market value of $849,738 based on the filing date. This represents a relatively small portion of the fund's holdings and the company's $3.0B market cap, but the sale comes amid heavy recent insider selling ($13.2M over 30 days) and may signal a gradual exit by a founding investor.
Key Facts
- Atlas Venture Opportunity Fund I, L.P. filed Form 144 to sell 47,103 shares of DYN common stock.
- Estimated aggregate market value of the proposed sale is $849,738.12.
- The shares were acquired in a private placement on August 7, 2020.
- Over the past 30 days, there have been 10 insider sells totaling $13.2M.
- The company has a market cap of approximately $3.0B.
- The filing date is April 28, 2026.
Financial Impact
Proposed sale of ~$850K in stock, representing a small fraction of the company's $3.0B market cap.
Risk Factors
- Continued insider selling could pressure the stock price.
- The sale by a prominent early investor may signal reduced confidence in near-term prospects.
- Heavy insider selling cluster may precede negative news or a downturn.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-027983 |
| Document: 0001628280-26-027983-index.html | 0001628280-26-027983 |
| Document: 0001628280-26-027983.txt | 0001628280-26-027983 |
Track record
54 reports on DYN
12 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 15 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers